LCPP Products May be Breakthroughs in Several Fields
Expand and revolutionize osteoporosis and HRT markets with Pfizer and AHP SERMs
Fulfill the promise of PPARs for oral therapy of Type II diabetes and bring a new mechanism to dyslipidemia with Lilly and Glaxo next-generation PPARs
Pioneer an emerging class of oral SARMs for hypogonadism, osteoporosis and sexual dysfunction with TAP
Revolutionize oral anti-inflammatory agents with selective GR modulators with Abbott, and with Ligand products for oncology / inflammatory diseases